Oxford BioMedica (LON:OXB)‘s stock had its “buy” rating restated by investment analysts at Peel Hunt in a research report issued to clients and investors on Monday. They presently have a GBX 13 ($0.17) price target on the biopharmaceutical company’s stock. Peel Hunt’s target price indicates a potential upside of 17.86% from the company’s previous close.

Shares of Oxford BioMedica (LON:OXB) opened at GBX 11.03 ($0.15) on Monday. Oxford BioMedica has a fifty-two week low of GBX 3.77 ($0.05) and a fifty-two week high of GBX 11.25 ($0.15).

In other Oxford BioMedica news, insider Lorenzo Tallarigo bought 29,365 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The shares were acquired at an average cost of GBX 9 ($0.12) per share, for a total transaction of £2,642.85 ($3,533.69). Insiders purchased a total of 90,662 shares of company stock worth $815,958 over the last quarter.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/oxford-biomedica-oxb-stock-rating-reaffirmed-by-peel-hunt/1798247.html.

Oxford BioMedica Company Profile

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with Analyst Ratings Network's FREE daily email newsletter.